• Cullen/Frost Bankers, Inc. recently reported fourth-quarter and full-year 2025 results showing higher net income and earnings per share versus the prior year, while also detailing lower net charge-offs and confirming both common and preferred stock dividends.
• Alongside these results, the board completed a prior buyback tranche and authorized a new US$300 million share repurchase program, signaling management’s confidence through continued capital returns.
• Next, we’ll look at how the stronger earnings and newly authorized US$300 million buyback shape Cullen/Frost’s broader investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 33 companies in the world exploring or producing it. Find the list for free.

What Is Cullen/Frost Bankers' Investment Narrative?

To own Cullen/Frost, you have to be comfortable with a fairly mature, slower‑growth regional bank that leans on steady profitability, disciplined credit and consistent dividends rather than big expansion. The latest results, with higher earnings, wider margins and meaningfully lower net charge‑offs, reinforce that story more than they change it, and the new US$300 million buyback adds another layer of capital return on top of the US$1.00 common dividend. In the near term, the main catalysts still sit around net interest income resilience and credit quality holding up, while the key risks remain modest earnings growth expectations and a valuation that screens richer than many banking peers. The new buyback and solid quarter modestly strengthen the bull case, but they do not erase those constraints.

However, investors should not ignore the risk that earnings growth expectations remain quite muted. Despite retreating, Cullen/Frost Bankers' shares might still be trading 18% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Four Simply Wall St Community fair value views span from about US$119 to a very large US$101,835, underlining how far apart individual expectations can be. Set that against today’s backdrop of modest forecast profit growth and richer peer comparisons, and it becomes even more important to weigh several viewpoints before deciding how Cullen/Frost fits into your portfolio.

Explore 4 other fair value estimates on Cullen/Frost Bankers - why the stock might be a potential multi-bagger!

Build Your Own Cullen/Frost Bankers Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Cullen/Frost Bankers research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Cullen/Frost Bankers research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cullen/Frost Bankers' overall financial health at a glance.

No Opportunity In Cullen/Frost Bankers?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.